Austar Lifesciences (6118) Stock Overview
An investment holding company, engages in the provision of integrated engineering solutions to pharmaceutical manufacturers and research institutes in Mainland China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
6118 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Austar Lifesciences Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$1.12 |
| 52 Week High | HK$1.97 |
| 52 Week Low | HK$0.45 |
| Beta | 1.56 |
| 1 Month Change | -14.50% |
| 3 Month Change | -20.57% |
| 1 Year Change | 96.49% |
| 3 Year Change | -18.25% |
| 5 Year Change | -68.89% |
| Change since IPO | -68.63% |
Recent News & Updates
Austar Lifesciences Limited's (HKG:6118) Share Price Boosted 27% But Its Business Prospects Need A Lift Too
Oct 09
Austar Lifesciences (HKG:6118) Has A Pretty Healthy Balance Sheet
Oct 09Recent updates
Austar Lifesciences Limited's (HKG:6118) Share Price Boosted 27% But Its Business Prospects Need A Lift Too
Oct 09Austar Lifesciences (HKG:6118) Has A Pretty Healthy Balance Sheet
Oct 09Austar Lifesciences Limited (HKG:6118) Shares Fly 54% But Investors Aren't Buying For Growth
Jul 22Here's Why It's Unlikely That Austar Lifesciences Limited's (HKG:6118) CEO Will See A Pay Rise This Year
May 16Austar Lifesciences (HKG:6118) Strong Profits May Be Masking Some Underlying Issues
May 01Austar Lifesciences Limited's (HKG:6118) Prospects Need A Boost To Lift Shares
Feb 17Austar Lifesciences Limited's (HKG:6118) Share Price Boosted 32% But Its Business Prospects Need A Lift Too
Oct 16Investors Aren't Buying Austar Lifesciences Limited's (HKG:6118) Revenues
Aug 28We Think Shareholders May Want To Consider A Review Of Austar Lifesciences Limited's (HKG:6118) CEO Compensation Package
May 24Revenues Working Against Austar Lifesciences Limited's (HKG:6118) Share Price Following 30% Dive
Apr 18Would Austar Lifesciences (HKG:6118) Be Better Off With Less Debt?
Mar 28Investors Still Aren't Entirely Convinced By Austar Lifesciences Limited's (HKG:6118) Revenues Despite 25% Price Jump
Feb 12Market Cool On Austar Lifesciences Limited's (HKG:6118) Revenues
Dec 22We Think Austar Lifesciences (HKG:6118) Has A Fair Chunk Of Debt
Sep 28Here's Why Austar Lifesciences (HKG:6118) Has A Meaningful Debt Burden
Mar 31Austar Lifesciences Limited (HKG:6118) Stock's 29% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Sep 19Is Austar Lifesciences (HKG:6118) A Risky Investment?
Apr 06Austar Lifesciences (HKG:6118) Has A Pretty Healthy Balance Sheet
Oct 24With EPS Growth And More, Austar Lifesciences (HKG:6118) Is Interesting
Sep 27If You Like EPS Growth Then Check Out Austar Lifesciences (HKG:6118) Before It's Too Late
May 31Austar Lifesciences (HKG:6118) Seems To Use Debt Quite Sensibly
Mar 31Is Now The Time To Put Austar Lifesciences (HKG:6118) On Your Watchlist?
Mar 01Austar Lifesciences Limited (HKG:6118) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ?
Feb 01
Are Austar Lifesciences's (HKG:6118) Statutory Earnings A Good Guide To Its Underlying Profitability?
Jan 11Austar Lifesciences (HKG:6118) Seems To Use Debt Quite Sensibly
Dec 21Can You Imagine How Jubilant Austar Lifesciences' (HKG:6118) Shareholders Feel About Its 191% Share Price Gain?
Dec 07Here's What Austar Lifesciences Limited's (HKG:6118) Shareholder Ownership Structure Looks Like
Nov 23Shareholder Returns
| 6118 | HK Life Sciences | HK Market | |
|---|---|---|---|
| 7D | 3.7% | -6.0% | 1.9% |
| 1Y | 96.5% | 95.4% | 30.1% |
Return vs Industry: 6118 exceeded the Hong Kong Life Sciences industry which returned 95.4% over the past year.
Return vs Market: 6118 exceeded the Hong Kong Market which returned 30.1% over the past year.
Price Volatility
| 6118 volatility | |
|---|---|
| 6118 Average Weekly Movement | 16.9% |
| Life Sciences Industry Average Movement | 7.5% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in HK Market | 15.0% |
| 10% least volatile stocks in HK Market | 3.3% |
Stable Share Price: 6118's share price has been volatile over the past 3 months compared to the Hong Kong market.
Volatility Over Time: 6118's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1991 | 1,446 | Mars Ho | www.austar.com.hk |
Austar Lifesciences Limited, an investment holding company, engages in the provision of integrated engineering solutions to pharmaceutical manufacturers and research institutes in Mainland China and internationally. The company operates through Integrated Process and Packaging Equipment & Systems (IPS); Consulting, Digitalization and Construction (CDC); and Life Science Equipment and Consumables (SIC) segments. It also offers clean utility and bioprocess equipment, clean room, automation control and monitor system; bioprocess equipment consumables, and laboratory solutions.
Austar Lifesciences Limited Fundamentals Summary
| 6118 fundamental statistics | |
|---|---|
| Market cap | HK$548.46m |
| Earnings (TTM) | HK$38.45m |
| Revenue (TTM) | HK$1.60b |
Is 6118 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6118 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.46b |
| Cost of Revenue | CN¥1.17b |
| Gross Profit | CN¥294.94m |
| Other Expenses | CN¥259.74m |
| Earnings | CN¥35.20m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.069 |
| Gross Margin | 20.18% |
| Net Profit Margin | 2.41% |
| Debt/Equity Ratio | 40.8% |
How did 6118 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/10 11:38 |
| End of Day Share Price | 2025/11/10 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Austar Lifesciences Limited is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Forrest Chan | CCB International Securities Limited |
| Tsz Man Chan | KGI Securities Co. Ltd. |